The FDA launched a safety review of birth control pills that contain drospirenone, in light of two recent studies in the British Medical Journal concluding that such products cause a higher risk of blood clots than levonorgestrel-based contraceptives. The finding conflicts with some previous studies that also compared the synthetic hormones, the agency said. The FDA is "evaluating the conflicting results from these studies and will look at all currently available information to fully assess the risks and benefits of drospirenone."

Related Summaries